Delivery Order SPE2DB20D3103-SPE2DB25FN5E4
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8.55K to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Mekinist 0.5 mg tablets (30-count units). This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 4, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $17,104.98 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Mekinist 0.5 mg tablets (30-count units). This competitively awarded, firm fixed-price contract carries an ultimate completion date of September 25, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor supporting federal medical supply needs,...
- The Defense Logistics Agency awarded a $40,764.88 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Mekinist 2 mg tablets (30-count units) on November 3, 2025, with an ultimate completion date of November 25, 2025. This is a non-set-aside competitive award issued as a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The place of performance is listed as Conshohocken, Pennsylvania, where the contractor maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Mekinist 2 mg tablets (30-count units) valued at $9,670.51 with a firm fixed price structure. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 25, 2025, and will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $19.3K to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Mekinist 2 mg tablets (30-count units). This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, scheduled for completion by June 23, 2025. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child delivery order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,850.83 to AmerisourceBergen Drug Corp for the supply of Mekinist 0.5 mg tablets (30-count units) under a firm fixed price contract. The delivery order, issued on October 27, 2025, with a completion date of November 18, 2025, represents a non-competitive, non-set-aside award to support federal pharmaceutical procurement needs. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $19,341.02 on July 22, 2025, for the supply of Mekinist 2 mg tablets (30-count units). This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of August 12, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $19,566.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Mekinist 2 mg tablets (30-count units) under a non-competitive delivery order mechanism. The contract was awarded on November 10, 2025, with an ultimate completion date of December 3, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine pharmaceutical procurement supporting the...
- The Defense Logistics Agency awarded a $18,566.92 delivery order to AmerisourceBergen Drug Corp on July 15, 2025, for the supply of Mekinist 2 mg tablets (30-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 5, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mekinist is a targeted cancer therapy medication, reflecting the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Mekinist 0.5 mg tablets in quantities of 30s, with a contract ceiling value of $5,701.68 and an ultimate completion date of October 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FN5E4Delivery Order
The Defense Logistics Agency awarded a $19.3K delivery order to AmerisourceBergen Drug Corp on April 21, 2025, for the supply of Mekinist 2 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with a completion date of May 12, 2025, and performance based in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order represents a child contract under AmerisourceBergen Drug Corp's significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.9M through December 2026. The IDC functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceuticals and medical supplies to support military healthcare programs worldwide. The company's federal contract portfolio demonstrates extensive capability in fulfilling diverse pharmaceutical needs across multiple therapeutic domains through competitively awarded arrangements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.3k | 4/21/25 |